AstraZeneca used its robust Q2 update to express hopes that Phase III data from of its COVID-19 vaccine candidate this year could provide it with a regulatory pathway. It is also entering a mAb combination into the clinic as a promising approach against COVID-19.
AstraZeneca PLC has said it should have Phase III data for its COVID-19 vaccine AZD1222 later in 2020 that might be sufficient for regulatory approval but stressed that the vaccine won't be a revenue driver if successful, as the group is focused on distributing it at a non-profit level.
The company updated markets on its COVID-19 response as it released another healthy set of quarterly financial results at this...
Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.
Lynkuet will compete with Astellas's Veozah/Veoza
Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
The osteogenesis imperfecta drug stumbled in a second interim analysis.
The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.
Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers
